Compounds > quinuclidines
Page last updated: 2024-08-18

quinuclidines and Cancer of Cervix

quinuclidines has been researched along with Cancer of Cervix in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hanawa, S; Mitsuhashi, A; Nishikimi, K; Shozu, M; Tate, S; Uno, T; Usui, H; Watanabe-Nemoto, M; Yamamoto, N1
Christensen, TB; Dohn, LH; Feyer, P; Halekoh, U; Hansen, O; Herrstedt, J; Hilpert, F; Keefe, D; Kristensen, G; Paludan, M; Ruhlmann, CH; Rønnengart, E1
Hanawa, S; Matsuoka, A; Mitsuhashi, A; Nishikimi, K; Shozu, M; Tate, S; Uno, T; Usui, H1

Trials

3 trial(s) available for quinuclidines and Cancer of Cervix

ArticleYear
The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II Study.
    American journal of clinical oncology, 2017, Volume: 40, Issue:2

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Middle Aged; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Treatment Outcome; Uterine Cervical Neoplasms; Vomiting

2017
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dexamethasone; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Uterine Cervical Neoplasms; Vomiting

2016
Efficacy of palonosetron plus aprepitant in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a phase II study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:11

    Topics: Adult; Aged; Aprepitant; Chemoradiotherapy; Cisplatin; Drug Therapy, Combination; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Uterine Cervical Neoplasms; Vomiting

2016